Nabriva gets FDA approval novel antibiotic Xenleta

Nabriva gets FDA approval for novel antibiotic Xenleta

9:33 AM, 20th August 2019
XENLETA Expected to be Available mid-September 2019

DUBLIN, IRELAND: Nabriva Therapeutics plc said that the US Food and Drug Administration (FDA) has approved its new drug Xenleta (lefamulin) for the treatment of community-acquired bacterial pneumonia (CABP) in adults.

Xenleta is available for oral (600 mg every 12 hours) and IV (150 mg every 12 hours) administration with a short 5-to-7-day course of therapy.

Nabriva expects Xenleta will be available through major U.S. specialty distributors in mid-September 2019. Xenleta will have a wholesale acquisition (WAC) price of $205 per IV patient treatment day and $275 per oral patient treatment day.

“Today’s approval of Xenleta is a significant breakthrough in the collective fight against the growing threat of antimicrobial resistance and provides a desperately needed IV and oral empiric monotherapy treatment option for adults with CABP,” said Ted Schroeder, chief executive officer of Nabriva Therapeutics.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Grace licenses Unipol technology to PetroChina

COLUMBIA, US: W. R. Grace & Co has licensed its Unipol PP Process Technology to PetroChina Guangdong Petrochemical Company Limited. Located i ...

Read more
SK Capital to acquire Polyone’s performance products & solutions biz

NEW YORK, US: SK Capital has signed a definitive agreement to acquire the Performance Products & Solutions business (PP&S) from PolyOne Corpor ...

Read more
McDermott begins commercial operation of Cameron LNG Train 1

HOUSTON, US: McDermott International Inc has begun commercial operation with Train 1 by joint owners Sempra LNG, LLC, Total, Mitsui & Co Ltd and J ...

Read more
BASF becomes founding member of value balancing alliance e.V.

LUDWIGSHAFEN, GERMANY: Together with seven international companies of the recently founded “value balancing alliance e.V.”, based in Frank ...

Read more
Covestro partners with industry and university in wind energy project

LEVERKUSEN, GERMANY: The wind energy industry dreams of developing maintenance-free systems. One important hurdle on the path to achieving this goal i ...

Read more
SII introduces first-ever heat-stable Rotavirus vaccine in the world, Rotasiil

PUNE, INDIA: In a landmark development, the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X